MarketingRx roundup: Neurocrine amps tardive dyskinesia campaign; FDA study finds animation has little effect in DTC ads
A new TV ad bolsters Neurocrine Bioscience’s campaign for tardive dyskinesia drug Ingrezza that began last spring. The commercial features patients …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
